×

NeoStem to Present at Multiple September Conferences

NeoStem Inc. Logo

NEW YORK, Sept. 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in September.

European Society of Cardiology Congress: Acute Cardiac Care 2013

  • Date and Time: Tuesday, September 3, 3:30 PM CEST
  • Venue: Congress Centre, Amsterdam, The Netherlands
  • Session: Infarction acute phase STEMI (Moderated posters)
  • Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and Regulatory Affairs

Rodman & Renshaw 15th Annual Healthcare Conference

  • Date and Time: Monday, September 9, 10:50 AM EDT
  • Venue: Millennium Broadway Hotel, New York, New York
  • Session: Company presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

International Society for Cellular Therapy (ISCT) North American Regional Meeting 2013

  • Date and Time: Tuesday, September 10, 10:30 AM EDT
  • Venue: Hyatt at Penn's Landing, Philadelphia, Pennsylvania
  • Session: Commercialization Case Study: Cell Therapy from Concept to Market
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, Progenitor Cell Therapy (PCT)

Stifel Annual Healthcare Conference 2013

  • Date and Time: Wednesday, September 11, 2:40 PM EDT
  • Venue: Four Seasons Hotel, Boston, Massachusetts
  • Session: Company presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

Heart Failure Society of America 17th Annual Scientific Meeting

  • Date and Time: Monday, September 23, 4:00 PM EDT
  • Venue: The Peabody Orlando Hotel, Orlando, Florida
  • Session: Can Cell Therapy Put Systolic Heart Failure on the Endangered Species List?
  • Speaker: Douglas W. Losordo, MD, FACC, FAHA, Chief Medical Officer

Aegis Capital Corp. 2013 Healthcare Conference

  • Date and Time: Thursday, September 26, 9:00 AM PDT
  • Venue: The Encore at Wynn, Las Vegas, Nevada
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

BioCentury Newsmakers in the Biotech Industry

  • Date and Time: Friday, September 27, 10:00 AM EDT
  • Venue: The Millennium Broadway Hotel & Conference Center, New York, New York
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

The Symposium on Advanced Wound Care

  • Date and Time: Saturday, September 28, 4:10 PM PDT
  • Venue: Bally's Las Vegas, Las Vegas, Nevada
  • Session: Cell Therapy for Critical Limb Ischemia
  • Speaker: Douglas W. Losordo, MD, FACC, FAHA, Chief Medical Officer

Stem Cells & Regenerative Medicine Congress

  • Date and Time: Monday, September 30, 1:50 PM EDT
  • Venue: The Hyatt Regency, Cambridge, Massachusetts
  • Session: Capital formation strategies for stem cell and regenerative medicine companies
  • Session Chair: Robin L. Smith, MD, MBA, Chairman and CEO

About NeoStem

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards development of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: NeoStem Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com

Source:NeoStem Inc.